Brief: JW (Cayman) Therapeutics Announces Potential Further Strategic Partnership With 2Seventy Bio
Sept 12 (Reuters) - JW (Cayman) Therapeutics Co Ltd
2126.HK :
* POTENTIAL FURTHER STRATEGIC PARTNERSHIP WITH 2SEVENTY BIO,
INC.
* ANNOUNCE ITS INTENTION TO EXPAND ITS STRATEGIC ALLIANCE
WITH
2SEVENTY BIO, INC
* COLLABORATION BUILDS UPON CO AND 2SEVENTY BIO'S
TRANSLATIONAL
AND CLINICAL CELL THERAPY DEVELOPMENT PLATFORM
* CO AND 2SEVENTY BIO INTEND TO CO-DEVELOP FURTHER
CANDIDATES FROM
PORTFOLIO OF 2SEVENTY BIO
* POTENTIAL COLLABORATION WITH 2SEVENTY BIO, INC. MAY OR MAY
NOT
PROCEED
Further company coverage: 2126.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License